Filtered By:
Cancer: Cancer
This page shows you your search results in order of date. This is page number 16.
Order by Relevance | Date
Total 426956 results found since Jan 2013.
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors
CONCLUSIONS: By disrupting an adaptive stress response evoked by VEGFR-TKIs, HC-5404 presents a clinical opportunity to improve the antitumor effects of well-established standard of care therapies in RCC.PMID:37733811 | DOI:10.1158/1078-0432.CCR-23-1182
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Michael E Stokes Veronica Calvo Sho Fujisawa Crissy Dudgeon Sharon Huang Nupur Ballal Leyi Shen Jennifer Gasparek Matthew Betzenhauser Simon J Taylor Kirk A Staschke Alan C Rigby Mark J Mulvihill Nandita Bose Eric S Lightcap David Surguladze Source Type: research
Differential benefit of metronomic chemotherapy among triple negative breast cancer subtypes treated in the IBCSG Trial 22-00
CONCLUSIONS: Our results show a differential benefit of low-dose CM therapy across different TNBC subtypes. Low-dose CM therapy could be considered as a potential immunomodulatory strategy for TNBC tumors with IM subtype in the early-disease setting.PMID:37733800 | DOI:10.1158/1078-0432.CCR-23-1267
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Andrea Joaquin Garcia Mattia Rediti David Venet Samira Majjaj Roswitha Kammler Elisabetta Munzone Lorenzo Gianni Beat Th ürlimann Istv án Láng Marco Colleoni Sherene Loi Giuseppe Viale Meredith M Regan Laurence Buisseret Fran çoise Rothé Christos Sot Source Type: research
ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC
CONCLUSIONS: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.PMID:37733794 | DOI:10.1158/1078-0432.CCR-23-1122
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Natalie I Vokes Ana Galan Cobo Margarita Fernandez-Chas David Molkentine Santiago Trevi ño Vitaly Druker Yu Qian Sonia Patel Stephanie Schmidt Lingzhi Hong Jeff Lewis Waree Rinsurongkawong Vadeerat Rinsurongkawong J Jack Lee Marcelo V Negrao Don L Gibbon Source Type: research
Near-infrared spectral tomography for predicting residual cancer burden during early stage neoadjuvant chemotherapy for breast cancer
CONCLUSION: NIRST holds promise as a potential clinical tool that can be seamlessly integrated into existing clinical workflow within the infusion suite. By providing early assessment of RCB, NIRST has potential to improve breast cancer patient management strategies.PMID:37733788 | DOI:10.1158/1078-0432.CCR-23-1593
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Xu Cao Kristen E Muller Mary D Chamberlin Jiang Gui Peter A Kaufman Gary N Schwartz Roberta M DiFlorio-Alexander Brian W Pogue Keith D Paulsen Shudong Jiang Source Type: research
Personalized Medicine's Coming of Age: One Drug, One Patient
Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-2194. Online ahead of print.ABSTRACTA dendritic cell/myeloma fusion vaccine, given with lenalidomide and GM-CSF, did not result in a statistically significant increase in CR rates at 1-year post-transplant but was associated with a significant increase in circulating multiple myeloma-reactive lymphocytes indicative of tumor-specific immunity.PMID:37733765 | DOI:10.1158/1078-0432.CCR-23-2194
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Muzaffar H Qazilbash Larry W Kwak Source Type: research
10-Patient Trial: Remarkable Responses in Pediatric Cancers
Clin Cancer Res. 2023 Sep 21. doi: 10.1158/1078-0432.CCR-23-2232. Online ahead of print.ABSTRACTA clinical trial of Nivolumab in 10 pediatric cancer patients with high tumor mutational burden demonstrated complete responses in 50% of patients. This result recapitulates multiple clinical trial results in high mutation burden adult cancers and may redefine best practice in the setting of germline DNA mismatch repair-based susceptibility.PMID:37733329 | DOI:10.1158/1078-0432.CCR-23-2232
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Elaine R Mardis Source Type: research
AACR Cancer Centers Alliance: Fostering Collaboration and Innovation to Advance Lifesaving Scientific Discoveries for Patients
Clin Cancer Res. 2023 Sep 13:OF1-OF3. doi: 10.1158/1078-0432.CCR-23-2625. Online ahead of print.ABSTRACTBasic and clinical cancer research discoveries stemming from the nation's cancer centers have markedly improved outcomes for many cancer patients. Despite this forward momentum in our progress against this complex disease, cancer in all its forms remains a major public health challenge that touches the lives of nearly every American, either directly or indirectly. The newly formed AACR Cancer Centers Alliance will accelerate the pace of discovery by providing an ongoing mechanism for transferring new knowledge, sharing r...
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Carlos L Arteaga John L Cleveland Margaret Foti Ruben A Mesa Louis M Weiner Cheryl L Willman David A Tuveson Source Type: research
Deuterium Magnetic Resonance Imaging Using Deuterated Water-Induced 2H-Tissue Labeling Allows Monitoring Cancer Treatment at Clinical Field Strength
CONCLUSIONS: Deuterium MRI at 1.5T proved feasibility to track 2H distribution throughout mouse tissues during D2O administration and revealed a higher 2H accumulation in the tumor xenografts. This research demonstrated a promising successful method for preliminary assessment of radiotherapy and chemotherapy of cancer.PMID:37732903 | DOI:10.1158/1078-0432.CCR-23-1635
Source: Clinical Cancer Research - September 21, 2023 Category: Cancer & Oncology Authors: Hirofumi Asano Abdelazim Elsayed Elhelaly Fuminori Hyodo Ryota Iwasaki Yoshifumi Noda Hiroki Kato Koki Ichihashi Hiroyuki Tomita Masaharu Murata Takashi Mori Masayuki Matsuo Source Type: research
Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)
CONCLUSION: The trial reached its primary end point of biochemical control and PFS, suggesting a clinical advantage for SBRT in addition to first-line AAP treatment in patients with metastatic castration-resistant prostate cancer.PMID:37733977 | DOI:10.1200/JCO.23.00985
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Giulio Francolini Andrea Gaetano Allegra Beatrice Detti Vanessa Di Cataldo Saverio Caini Alessio Bruni Gianluca Ingrosso Rolando Maria D'Angelillo Anna Rita Alitto Matteo Augugliaro Luca Triggiani Silvana Parisi Gaetano Facchini Marco Banini Gabriele Simo Source Type: research
Aggressive variant prostate cancer: A case report and literature review
CONCLUSION: We should reach consensus definitions of the AVPC and other androgen receptor-independent subtypes of PCA and develop new biomarkers to identify groups of high-risk variants. It is crucial to complete a puncture biopsy of the tumor or metastatic lesion as soon as possible in patients with advanced PCA who exhibit clinical features such as low Prostate-specific antigen levels, high carcinoembryonic antigen levels, and insensitivity to hormones to determine the pathological histological type and to create a more aggressive monitoring and treatment regimens.PMID:37731555 | PMC:PMC10507546 | DOI:10.12998/wjcc.v11.i26.6213
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xiang-Tao Weng Wen-Li Lin Qi-Man Pan Tao-Fen Chen Si-Yi Li Chi-Ming Gu Source Type: research
Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum
Clin Lung Cancer. 2023 Aug 30:S1525-7304(23)00181-X. doi: 10.1016/j.cllc.2023.08.016. Online ahead of print.NO ABSTRACTPMID:37734987 | DOI:10.1016/j.cllc.2023.08.016
Source: Clinical Lung Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Tilmann Bochtler Petros Christopoulos Kai Schlamp Frank Winkler Alwin Kr ämer Source Type: research
ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC
CONCLUSIONS: ATM mutations define a distinct subset of NSCLC associated with KRAS mutations, increased TMB, decreased TP53 and EGFR co-occurrence, and potential increased sensitivity to ICIs in the context of DNA-damaging chemotherapy.PMID:37733794 | DOI:10.1158/1078-0432.CCR-23-1122
Source: Clinical Lung Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Natalie I Vokes Ana Galan Cobo Margarita Fernandez-Chas David Molkentine Santiago Trevi ño Vitaly Druker Yu Qian Sonia Patel Stephanie Schmidt Lingzhi Hong Jeff Lewis Waree Rinsurongkawong Vadeerat Rinsurongkawong J Jack Lee Marcelo V Negrao Don L Gibbon Source Type: research
CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels
CONCLUSIONS: A threshold effect is shown to exist between the peripheral blood CD4 and distant metastasis in NSCLC patients. It was revealed that the risk of distant metastasis is lower when CD4 is maintained between 32 and 44%, whereas low (< 32%) or high (> 44) levels of CD4 are associated with an increased risk of distant metastasis in NSCLC patients.PMID:37733240 | DOI:10.1007/s00432-023-05418-2
Source: Clinical Lung Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Ying Bai Yafeng Liu Jing Wu Rui Miao Zhi Xu Chunxiao Hu Jiawei Zhou Jianqiang Guo Jun Xie Zilun Shi Xuansheng Ding Yingru Xing Dong Hu Source Type: research
Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study
CONCLUSIONS: Although the overall rate of pneumonitis in patients receiving TRT and osimertinib was relatively low, there was a small risk of severe toxicity. The mean lung dose was associated with an increased risk of developing pneumonitis. These findings inform decision-making for patients and providers.PMID:37732171 | PMC:PMC10507641 | DOI:10.1016/j.jtocrr.2023.100559
Source: Clinical Lung Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Leou Ismael Banla Alice Tzeng John P Baillieul Melin J Kandekhar Kelly J Fitzgerald Jaclyn LoPiccolo Holly A Poitras Daniel E Soto Julia K Rotow Lisa Singer Henning Willers David E Kozono Pasi A Janne Raymond H Mak Zofia Piotrowska Florence K Keane Benjam Source Type: research
Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment
CONCLUSIONS: Subtype of SCLC generally remains the same after acquiring chemotherapy resistance. Plasticity was observed with rare cases switching from NEUROD1-predominant to ASC1-predominant SCLC. Resubtyping is unnecessary for the consideration of novel subtype-specific targeted agents, except cases with NEUROD1-predominant subtype.PMID:37731627 | PMC:PMC10507151 | DOI:10.1016/j.jtocrr.2023.100561
Source: Clinical Lung Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Ying-Chun Lo Joel Rivera-Concepcion George Vasmatzis Marie-Christine Aubry Konstantinos Leventakos Source Type: research
